Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp alfa vs Pembrolizumab in PD-L1 high advanced NSCLC
NCT03631706Phase 3Completed
- Sponsor
- EMD Serono
- Start
- Oct 2018
- Primary completion
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of bintrafusp alfa in non-small cell lung cancer (NSCLC) (2 arms), sponsored by EMD Serono. Primary endpoints: Progression-Free Survival up to 746 days and Overall Survival up to 843 days. Started Oct 2018; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03631706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03631706.